JPMorgan lowered the firm’s price target on Ideaya Biosciences to $55 from $57 and keeps an Overweight rating on the shares following a model update. Key changes to the model include expenses and share count, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences reports Q1 EPS (53c), consensus (51c)
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Ideaya Biosciences announces selection of move-forward expansion dose for IDE397
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal